Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Bioharvest Sciences (BHST) Long-Term Debt Repayments (2024 - 2025)

Bioharvest Sciences has reported Long-Term Debt Repayments over the past 2 years, most recently at $2.3 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 106.61% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $1.4 million, up 99.42%, while the annual FY2025 figure was $1.4 million, 99.42% up from the prior year.
  • Long-Term Debt Repayments was $2.3 million for Q4 2025 at Bioharvest Sciences, up from -$424000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $2.3 million in Q4 2025 and bottomed at -$424000.0 in Q3 2025.